Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
July 02, 2020 11:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
May 28, 2020 08:00 ET
|
ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
Business Capital Delivers $5.5 Million Financing for Wedderspoon
January 14, 2020 07:00 ET
|
Business Capital
SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered a $5.5MM working capital facility for Wedderspoon, the largest seller of Manuka honey and its portfolio of...
Animal Drugs Market value to hit $41 billion by 2025: Global Market Insights, Inc.
December 01, 2019 20:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Dec. 01, 2019 (GLOBE NEWSWIRE) -- Global Animal Drugs Market is set to cross USD 41 billion by 2025, according to a new research report by Global Market Insights, Inc....
Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference
October 22, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference
October 11, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
August 02, 2018 08:00 ET
|
Celtaxsys, Inc.
-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients --Celtaxsys,...
Trivedi Global, Inc. and Kathryn Sweas Announce Research Results of a Biofield Energy Treated Nutraceutical to Mitigate Inflammation and Autoimmune Disorders
July 10, 2018 10:00 ET
|
Trivedi Global, Inc.
Portland, Oregon, USA, July 10, 2018 (GLOBE NEWSWIRE) -- Kathryn Sweas, an evidence-based energy healer, today announces the impact of a biofield energy treated nutraceutical to increase immunity...
Trivedi Global, Inc. and Maire Mayne Announce Research Results on the Impact of an Energy Treated Nutraceutical for Reducing Autoimmune and Inflammatory Disorders
July 09, 2018 12:34 ET
|
Trivedi Global, Inc.
London, United Kingdom, July 09, 2018 (GLOBE NEWSWIRE) -- Maire Mayne, an energy healer with scientifically validated abilities, today announces the outcome of preclinical research on a proprietary...